DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Menu-Site Contactexpress Faqs Legends Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | Alizé Pharma | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Aterovax | Atlantic Bone Screen | Aureus Sciences | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-Modeling) | Carmat | Cellectis | Cellial Technologies | CellProthera | CellVax | Cerenis Therapeutics | CliniGenetics | Covalab | Cytheris | Cytoo | DBV Technologies | Diaxonhit | DNA Therapeutics | Domain Therapeutics | Dynabio | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | Genticel | GTP Technology | Helios Biosciences | Hemarina | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | MABlife | Magnisense | Mapreg | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MilleGen | Murigenetics | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NewVectys | NicOx | Nokad | Nosopharm | NovAliX | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | OriBase Pharma | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | Proteogenix | Protexel | PX'Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sisène Biotechnologies | Skuld-Tech | Stentys | Synapcell | Synprosis | Tc Land Expression | Theraclion | Theradiag | Theralpha | TheraVectys | Transgene | Trophos | TxCell | UROsphere | Vaxon Biotech | Vectalys | Vivalis | XenTech |

* CYTOO *


 

2008 - Rhône-Alpes
Grenoble
www.cytoo.com

 

Contract, Research
Key words: Adhesive micropatterns, High Content Analysis, Cell based assays, Cell Screening
Mission: to develop, manufacture, and distribute products that make cellular analysis robust and reliable by drastically decreasing cell variability
Clients: Pharmaceutical industry
contact@cytoo.com

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.-CEO: Chatelain (François) [co-founder, born 1965, ex-CEA, Protogene, Life Technologies, Genset, DNAgency]
Sc.Dir.-CSO: Bornens (Michel) [co-founder, board member, ex-Pasteur Institute, Curie Institute]
Oper.Dir.-COO: Fuchs (Alexandra) [co-founder, born 1969, Ph.D. biochemistry, Eng. Centrale, ex-CEA]
Fin.Dir.-CFO: Fayand (Laurence) [EM-Lyon (MBA), ex-Fideco, Hewlett-Packard, Alditech, Crocus Technology (co-founder), Beamind]
BusDev: Sharp (William) [also President-CEO Cytoo Inc.]
Financers (Hist.): privately owned (registered capital 2008 = 0.1 M€), Auriga Partners, CEA Valorisation, Rhône-Alpes-Création, Expansinvest, Jacques Lewinern, Sham and Entrepreneurs Fund

Turnover (M€) : 0.03 (2009)
Total funding (M€) : 11.2
Last funding (M€) : 7.0
Focus : Consumables
Position : Trade
Company confirm : none

 

History
DATEMILESTONETYPETIME
2011 .12 Financing (grant) : 4.0 M€ (in part), by EU FP7 to launch Mehtrics, a public-private consortium, with Cenix BioScience and academic collaborators, to further develop high throughput and high content RNAi screening through convergence with micropatterning-based cell assays RFIN [3 years]
2011 .11 2nd round-financing : 7.0 M€, led by Sham and Entrepreneurs Fund (EF) and previous shareholders (Auriga and Jacques Lewiner) RFINB [3 years]
2010 .11 Launch of Cytooplates, for High Content Screening (HCS) MKTG [2 years]
2009 .09 Set-up of Cytoo Inc., US subsidiary (Boston) ORGC [1 year]
2009 .07 1st round-financing : 3.2 M€ by Auriga Partners and private investor RFINA [1 year]
2009 .04 Launch of Cytoochips, following worldwide exclusivity for adhesive cell micropattern technology from Curie Institute and CNRS (3 patents licensed-in), with on-line trading MKTG [0 year]
2009 .01 Company move to Miniatec (still in Grenoble), with 300 square meters facility RELOC [0 year]
2008 .10 Seed financing : 1.0 M€, by CEA Valorisation, Rhône-Alpes-Création, Expansinvest and private investors (undisclosed) SFIN [0 year]
2008 .06 Company founded by François Chatelain, Alexandra Fuchs, Jacques Lewiner, Michel Bornens ORGF [0 year]

Actualisation / Updating: 24-Feb-2012

   


Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT



© J.H. Huber, Pharmaclient 2001-2017. Pour retourner à la page d'accueil Biotech: BIENVENUE !       Haut de page : légende